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INTRODUCTION
Melanomas are malignant mesenchymal tumors originating from melanocytes. The primary location of origin is most often in the skin, eyes, mucosal surfaces of the head and neck area, anorectum, genitalia etc. Ultraviolet B radiation is the number one risk factor for the development of melanoma. 1 However, the anal mucosa is not an area exposed to sunlight and an underlining trigger for the development of anal melanoma is still widely unidentifi ed.
Primary melanomas of the anus and rectum are rare neoplasms with aggressive behavior, accounting for 0.1%-4.6% of anal canal tumors and less than 2% of all melanomas. [2] [3] [4] [5] A sampling of cancer registries in U.S. cities revealed an incidence of 1.7 cases per 1 million per year. 6 The median age at which the condition is diagnosed is 55 years, although ranging from 29 to 91 years of age. Certain areas of the world, such as Australia and New Zealand have a higher predominance of the condition. 7 Primary symptoms reported include bleeding, anal pain, palpable anal mass, anal pruritus, tenesmus, and change in bowel habits. If a metastatic disease is present, symptoms may also include medium to severe weight loss, anemia, generalized fatigue, groin masses, pelvic masses, or even bowel obstruction.
The diagnosis is often delayed, which combined with aggressive nature of the malignancy, leads to patients with anal melanoma frequently to be present with advanced distant systemic complaints. 8 Many cases are without pigmentation, clinically and histologically. Traditional hematoxylin & eosin (H&E) histology may not be suffi cient enough to confi rm the diagnosis. In such cases, immunohistochemistry is obligatory, with markers such as S-100, HMB-45, Melan A, and vimentin, which are intensively positive in 78-100% of anorectal melanomas. 9 Staging of anal melanoma differs from that of cutaneous melanoma, based on the Breslow classifi cation. Anorectal melanoma is staged on a combined clinical and pathological basis, focusing on the regional and distant spread, with stage 0 being an in situ lesion, I being a local disease only with a lesion measuring no more than 2 mm without ulceration, stage II a local disease with size more than 2 mm with ulceration and no regional lymph node spread, stage III any size of primary lesion and any involvement of regional lymph nodes, and stage IV indicates a distant spread to other organs or non-regional lymph nodes. 10 As already mentioned, bleeding often is the fi rst complaint, which marks an advanced stage of the disease, indicating limited treatment possibilities. On histological examination, the tumor was located in the submucosa of the linea dentata region and consisted of roundish large moderately atypical cells with vesicular nuclei (Fig. 1) . The cells formed nests with dark-black pigment granules between them (Fig. 1b) (Fig. 2) .
A strong positive reaction with CD 117 in more than 80% of the melanoma cells was also present (Fig. 3) 
DISCUSSION
Anorectal melanomas often are diagnosed late in their pathobiological development, resulting in poor prognosis. There is a tendency for alternative therapy application, often depending on the results of the mutational status of the tumor.
Taken together with their extreme rarity, 1.7 cases per one million, the diagnosis is extremely diffi cult based on clinical presentation alone, the clinical presentation can more often than not be mistaken for colorectal cancer, leading to delay or inadequate treatment or surgical procedures being undertaken. [2] [3] [4] [5] [6] Earlier symptoms of the tumor such as pseudoconstipation, feeling of a tender mass during defecation can also be mistaken for other conditions. Therefore in most cases the condition is already severely advanced and diagnosed in stage IV. Due to these facts however, the true incidence of anorectal melanoma may be signifi cantly higher as place of origin of metastatic melanoma, without unknown primary location, which in different populations based on statistical reports varies from 5 to 20%. 11, 12 Regardless of all factors in the epidemiology of anorectal melanoma, the pathogenesis of this distinct clinical entry varies severely from skin melanoma, due to the lack of several predisposing factors in the area. This baffl ing pathogenesis is also evident from the presence of several mutations, which vary signifi cantly from those observed in skin melanoma. 10 KIT mutations are most commonly detected in acral melanomas with 23% and in mucosal melanomas with 15.6%. They are seldom found in melanomas with other locations such as conjunctival, with 7.7% and cutaneous, with 1.7%. KIT copy number was also most commonly detected in acral, with 27% and mucosal melanomas, with 26%. [14] [15] [16] There is also a strong correlation with KIT gene alterations are immunoreactivity with CD117, thus an emphasis should be put on the CD117 status. [13] [14] [15] Thus a routine application of CD117 immunohistochemistry in pathological diagnosis is indicative with a predictive purpose. 7, 13 BRAF V600E mutations are reportedly identifi ed in 26.7% of conjunctival melanomas and 55.7% of cutaneous melanomas, but only in 1.1% of the mucosal melanomas. 17 The CD3, in this case, recognized most of the tumor-infi ltrating lymphocytes (TIL). There were a large number of TIL in the tumor sample forming multiple groups throughout. Furthermore TIL, as in this case, often correlate with the positive mutational status of the melanoma. 18 
CONCLUSION
Anorectal melanoma is an aggressive and rare malignancy, often presenting clinically late in its pathobiological behavior, with fi ve-year survival rate ranging from 3 to 22% and further survival in patients with recurrent or metastatic disease being less than 10 months. 7 There are currently no reported cases in the literature of long-term survivors, where metastatic disease is present.
Chemotherapy and targeted chemotherapy, radiation therapy, or both, in addition to surgery, are likely to provide the best available treatment options for metastatic disease in advanced anorectal melanoma. 7 
